Quantcast
Last updated on April 18, 2014 at 0:14 EDT

SI-BONE, Inc. Announces Spring Society Meeting Attendance

March 4, 2013

AANS/CNS: March 7th and 8th

SAN JOSE, Calif., March 4, 2013 /PRNewswire/ — SI-BONE, Inc. (San Jose, California), a medical device company that is pioneering the use of a minimally invasive surgical (MIS) device to fuse the sacroiliac (SI) joint announced today it will attend and exhibit at several major society meetings over the coming months including AANS/CNS Section, AAOS, ISASS and AANS. Later this week, the company will exhibit at the AANS/CNS Section Meeting on March 7(th) and 8(th) at the JW Marriott Desert Ridge in Phoenix, AZ in booth #100. As part of the AANS/CNS Section meeting, Dr. William Smith* from Las Vegas, NV will be speaking during the David Cahill Memorial Controversies session Saturday morning, March 9(th) on the benefits of MIS SI joint fusion for SI joint disorders. Later this month, SI-BONE will exhibit at the AAOS meeting from March 20(th) through 22(nd) in Chicago, IL in booth #655.

“We are excited to be supporting the Academy by attending and exhibiting at their annual meeting and we are looking forward to the opportunity to educate this diverse group of orthopedic specialists on the diagnosis and treatment of SI joint disorders,” said Jeffrey Dunn, President and CEO of SI-BONE. Following AAOS, the company will exhibit at ISASS in Vancouver, Canada from April 3(rd) through April 5(th) in booth #109. Three abstracts have been accepted and will be presented during poster sessions, including two by Dr. Leonard Rudolf*(1,2) and one by Dr. Donald Sachs*(3) on their respective clinical outcomes treating patients with iFuse. Finally, at the end of April, the company will exhibit at the AANS meeting in New Orleans, LA from April 29(th) through May 1(st) in booth #1142. During the meeting, Dr. Donald Sachs will present his clinical outcomes with iFuse during a poster session. Mr. Dunn commented: “These next few months provide a great opportunity for us to support these key societies and continue our mission to educate and collaborate with their membership on advancing the diagnosis and treatment of patients who suffer from SI joint disorders.”

SI-BONE, Inc. received original clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System for fracture fixation of long bones and large bone fragments of the pelvis for conditions including sacroiliac joint disruptions and degenerative sacroiliitis, and an additional clearance in April 2011 for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The CE mark for European commercialization was obtained in November 2010.

Clinical publications have identified the SI joint as a pain generator for up to 22% of low back pain patients.(4) In addition, DePalma et al, Pain Medicine 2011, identified the SI joint as a pain generator in low back pain in 40 to 61% of post-lumbar fusion patients, so-called “failed back surgery” patients.(5) Initial treatment options for patients with SI joint disorders typically involve non-surgical management and, when non-surgical treatment of the SI joint fails, surgical treatments such as the iFuse may provide an option.

The iFuse Implant System is a commercially available device in the U.S. and Europe. The iFuse procedure uses a small incision for delivery and implantation of titanium implants. The implants are coated with a porous, titanium plasma spray that acts as an interference surface, designed to help decrease implant motion and provide immediate fixation and long term fusion. These implants have substantial thickness and sophisticated metallurgy and are able to produce a much stronger construct than that of conventional screws used to surgically fix bony structures. The iFuse System is intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. As with all surgical procedures and permanent implants, there are risks and considerations associated with surgery and use of the iFuse Implant.

About SI-BONE, Inc.

SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to SI joint disorders. The company has developed, and is manufacturing and marketing, a less invasive approach using implants for the treatment of certain SI joint pathologies. SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices. SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2013 SI-BONE, Inc. All Rights Reserved. 8412.030113

*Physicians who also receive compensation from SI-BONE for providing consulting services.

(1)Rudolf Abstract: A-506-0000-00032. Title: “MIS Sacroiliac (SI) Joint Fusion in the Context of Previous Lumbar Spine Fusion: 50 Patients with 24 Month Follow up”. SI-BONE provided support for this study.

(2)Rudolf Abstract: A-506-0000-00031. Title: “Sacroiliac Joint Arthrodesis – MIS Technique with Titanium Implants: Report of the First 50 Patients and Outcomes with Minimum 24 Month Follow up”. SI-BONE provided support for this study.

(3)Sachs Abstract: A-506-0000-00500. Title: “One Year Successful Outcomes for Novel Sacroiliac Joint Arthrodesis System”. SI-BONE provided support for this study.

(4 )Bernard TN, Kirkaldy-Willis WH. Recognizing specific characteristics of nonspecific low back pain. Clinical Orthopedics 1987;217:266-80.

(5 )DePalma, M. Etiology of chronic LBP patients having undergone lumbar fusion. Pain Medicine, 2011;12:732-39.

SOURCE SI-BONE, Inc.


Source: PR Newswire